Source: biotech-capital.com
Over the past month Clinuvel Pharmaceuticals Limited (CUV.AX) saw a rise of 49.19% this marks it as the biggest earner within Australian Stock as I Know First predicted. This surge can be attributed to the anticipated FDA approval for its drug SCENESSE® a photo-protective drug used to treat a rare condition known as targeting erythropoietic protoporphyria (EPP). SCENESSE® is already approved by the EU in 2014 and was available from 2016 across Europe. In the first half of FY18, Clinuvel had revenue of just $7 million, enough to generate
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
